Literature DB >> 11210392

A look at the safety profile of over-the-counter naproxen sodium: a meta-analysis.

V Bansal1, T Dex, H Proskin, S Garreffa.   

Abstract

As the trend for Americans to self-medicate continues to increase, it becomes important to review the safety of over-the-counter (OTC) medications. This article will review the safety of an OTC analgesic, Aleve (naproxen sodium). The objective of this meta-analysis is to evaluate the frequency of occurrence of all adverse events in subjects taking various doses of OTC naproxen sodium as compared to placebo. These varying doses and dosage regimens were studied individually and consisted of 220 to 880 mg administered in single, multiple, and PRN (as needed) doses of naproxen sodium. This meta-analysis confirmed the favorable safety profile of naproxen sodium at OTC doses and established that the overall occurrence of adverse events with naproxen sodium was comparable and in some cases significantly lower than placebo. These results indicate that treatment with naproxen sodium may be highly beneficial from a clinical and economical perspective and safe when adhering to labeled directions.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11210392     DOI: 10.1177/00912700122009935

Source DB:  PubMed          Journal:  J Clin Pharmacol        ISSN: 0091-2700            Impact factor:   3.126


  3 in total

1.  Pain Treatment of Underserved Older African Americans.

Authors:  Hamed Yazdanshenas; Mohsen Bazargan; James Smith; David Martins; Hooman Motahari; Gail Orum
Journal:  J Am Geriatr Soc       Date:  2016-09-02       Impact factor: 5.562

2.  Nonsteroidal Anti-Inflammatory Drugs and Opioids in Postsurgical Dental Pain.

Authors:  E V Hersh; P A Moore; T Grosser; R C Polomano; J T Farrar; M Saraghi; S A Juska; C H Mitchell; K N Theken
Journal:  J Dent Res       Date:  2020-04-14       Impact factor: 6.116

3.  A patient with osteoarthritis and cardiovascular disease presenting with bilateral hip pain: a case report.

Authors:  Jennifer Yanow; Marco Pappagallo
Journal:  Cases J       Date:  2009-08-24
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.